The adaptive immune response is a major determinant of the clinical outcome after SARS-
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …

The pandemic of coronavirus disease 2019 (COVID‐19), caused by the severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused an unprecedented global …

Beyond their substantial protection of individual vaccinees, coronavirus disease 2019
(COVID-19) vaccines might reduce viral load in breakthrough infection and thereby further …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected 78 million
individuals and is responsible for over 1.7 million deaths to date. Infection is associated with …

In contrast to other respiratory viruses, children have less severe symptoms when infected
with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this …

Due to the high prevalence and long incubation periods often without symptoms, the severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals …

The kinetics of the immune changes in COVID-19 across severity groups have not been
rigorously assessed. Using immunophenotyping, RNA sequencing, and serum cytokine …

The coronavirus pandemic has significantly impacted solid organ transplantation (SOT).
Early in the outbreak period, transplant societies recommended suspending living kidney …

Although infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
pleiotropic and systemic effects in some individuals,–, many others experience milder …

Background To date, only monoclonal antibodies have been shown to be effective for
outpatients with COVID-19. Interferon lambda-1 is a type III interferon involved in innate …